What were the key drivers behind AFT Pharmaceuticals (ASX:AFP) revenue growth in FY26?

AFT Pharmaceuticals delivered a 22% increase in full-year operating revenue to NZ$254.7 million, driven by strong product sales and royalties across all territories. Growth was led by a 66% lift in international markets, a 41% rise in Asia, and a 19% expansion in Australia. Additionally, licensing income provided significant momentum, skyrocketing from NZ$0.7 million to NZ$3.1 million.

Did AFT Pharmaceuticals (ASX:AFP) meet its profit guidance for the financial year?

Yes, AFT Pharmaceuticals exceeded its expectations by posting a record operating profit of NZ$24.4 million. This result outpaced the company's initial FY26 guidance range of NZ$20 million to NZ$24 million.

What are the core profitability metrics for AFT Pharmaceuticals (ASX:AFP) following this update?

The company showed broad growth across its key profit metrics for the year ended March 31. EBITDA rose to NZ$28.8 million, while net profit after tax (NPAT) increased by 24% to NZ$14.1 million.

Is AFT Pharmaceuticals (ASX:AFP) paying a dividend this year?

Yes, retail investors will see an increased capital return as AFT Pharmaceuticals declared a dividend of 2.5 cents per share for the financial year. This is a notable step up from the 1.8 cents per share dividend paid in FY25.

What is the medium-term investment thesis for AFT Pharmaceuticals (ASX:AFP) after these results?

The investment thesis is shifting from a purely local Australasian play to a scaling international growth story. By successfully expanding into Asia and international markets—which grew 41% and 66% respectively—AFT is reducing its reliance on its home turf.

Image for illustrative purposes only. Not a real photo.

AFT Pharmaceuticals reports record FY26 profit and growth

Q: What is the financial guidance for AFT Pharmaceuticals (ASX:AFP) in FY27?

Looking forward, AFT Pharmaceuticals has issued formal FY27 guidance targeting an operating profit between NZ$28 million and NZ$32 million. Management is also officially targeting full-year revenue in excess of NZ$300 million.

Written by Heidi Cuthbert Published May. 20 2026Last Updated May. 20 2026

AFT Pharmaceuticals (ASX:AFP) has delivered a financial performance for the year ended March 31, reporting record earnings and double-digit revenue growth across all operating territories.

The Australasian pharmaceutical leader posted a 22% rise in full-year operating revenue, reaching NZ$254.7 million, up from NZ$208 million in FY25.

The growth was underpinned by a 21% increase in product sales and royalties, driven by a 19% expansion in Australia, a 41% rise in Asia, and a 66% lift in international markets.

Licensing income also saw momentum, skyrocketing to NZ$3.1 million from NZ$0.7 million in the previous year.

The company’s profitability metrics showed gains, with EBITDA rising to NZ$28.8 million and net profit after tax increasing by 24% to NZ$14.1 million.

AFT’s operating profit hit a record NZ$24.4 million, outpacing its initial guidance range of NZ$20 million to NZ$24 million.

The earnings acceleration offset substantial ongoing investments in research and development alongside international business hubs.

AFT declared an increased dividend of 2.5 cents per share, up from 1.8 cents in FY25.

Looking ahead, the company maintains a growth trajectory, issuing FY27 guidance for an operating profit between NZ$28 million and NZ$32 million whilst officially targeting revenue in excess of NZ$300 million.

Chair David Flacks and Managing Director Dr Hartley Atkinson credited the results to strategic execution, geographic diversification, and continued international expansion.